An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases.
VERDICT
The label
Markup
read at $105.60
Dianthus Therapeutics, Inc. holds its Markup at $105.60.
PHPhase · the trend structure carries the Markup label
INInsiders · no filings inside 60 days, left as found
POPositioning · no disclosures inside 60 days, left as found
OPOptions · no verdict drawn today, left as found
SCScreen · passes the values gate
edge confirmed
edge broken
edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
INVESTOR
The investor read · the season, not the day
As held on the ledger · 2026-07-19
Phase
Markup
Quantitative state
The statistical read favours the sellers, held for 55 days
Price
$105.60
Valuation
N/A trailing · -22.70 forward price to earnings
Values screen
PASS· score 70.0
Beta
0.09
OPPORTUNITY
The opportunity · what the numbers say it is worth
Read at
$105.60
N/A P/E · -22.70 fwd
Our fair value
$125.00
18% discount
Analyst target (avg)
$125.00
+18% to current
Target low $105.00Analyst target rangeTarget high $200.00
▲ current $105.60 · | average target
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Current
$105.60
you are here
Conservative
$105.00
-1%
Analyst avg
$125.00
+18%
Our fair value
$125.00
+18%
Analyst high
$200.00
+89%
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Revenue growth
-60.20%
Profit margin
0.00%
Debt to equity
0.11
Analyst consensus
Strong Buy · 12 covering
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
SCREEN
The values screen, explained · five checks, plain English
This company clears both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. Here is how it did on each:
The common standard· AAOIFI Used by most halal investing apps✓ PASSES
Our stricter standard· asset-based The one Titan applies✓ PASSES
Business activityIts core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending.Pass
Debt loadInterest-bearing debt is of its assets, above the one-third ceiling the screen allows.Fail
Interest-bearing cashInterest-bearing cash and securities are of assets, above the one-third limit.Fail
ReceivablesMoney owed to the company is of assets, above the 49% limit.Fail
Revenue purityOnly 0.0% of revenue comes from non-compliant sources — under the 5% line.Pass
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
PLAIN
The business, in plain words · what the numbers mean
Clinical stage bet with zero profits today
Picture a lab team betting the house on one antibody tweak that might tame brutal autoimmune flares. That is the whole story at Dianthus right now. The shares sit below our calculated fair value, yet the opportunity rating stays at none because the business has not crossed into real revenue or positive returns.
The numbers tell the same tale. Revenue is shrinking fast, margins sit at zero, and return on equity is deeply negative. Twelve analysts still cluster around a strong buy with a median target matching our fair value, but those targets rest on future trial success that has not arrived. Ethical screen clears, yet that alone does not turn a pre-profit clinical programme into an investable business.
Risk sits in the usual biotech trap. One failed study or delayed approval can wipe years of value while cash keeps burning. Unknown competitive moat and negative forward earnings leave little margin for the inevitable setbacks. Analysis, not advice.
Screened names in the same industry · explore each on its own page.
TRADE
Where & how to trade · wherever in the world you are
DNTH trades on Nasdaq. As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
TRADER
The trader read · the latest dated commentary
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 28.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 72% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 310%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (12 analysts) rates it strong buy, with a mean price target of $126. Entered 2026-07-26 · Accumulation
JOURNAL
The dated journal · newest first, never edited
2026-07-26Accumulation$105.60+28.7%Entry 4
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 28.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 72% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 310%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (12 analysts) rates it strong buy, with a mean price target of $126.
2026-07-18Accumulation$82.07+0.0%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 72% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 310%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (12 analysts) rates it strong buy, with a mean price target of $126.
2026-07-03Accumulation$82.07+0.0%Entry 2
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Accumulation$82.07Entry 1
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
RETURNS
What holding actually paid · price plus dividends
If $1,000 had been placed · historical, not a promise
Period
Price then
Price return
Divs per share
$1,000 became
Total return
1 month
$87.12
-11.7%
·
$883
-11.7%
2 months
$89.77
-14.3%
·
$857
-14.3%
3 months
$80.32
-4.3%
·
$957
-4.3%
6 months
$41.63
+84.7%
·
$1,847
+84.7%
1 year
$18.75
+310.1%
·
$4,101
+310.1%
2 years
$21.47
+258.2%
·
$3,582
+258.2%
3 years
$11.20
+586.6%
·
$6,866
+586.6%
5 years
$185.28
-58.5%
·
$415
-58.5%
Historical returns from market close data. Past performance does not guarantee future results.
SEALED
This entry now belongs to the ledger. Whatever DNTH does next, these words stay.
Dianthus Therapeutics, Inc. · DNTH · Markup · $105.60
Recorded 2026-07-19 · before the outcome · scored mechanically
